ZURICH (Reuters) – Novartis’s consumer health unit will take a $ 120 million hit in the fourth quarter after the Swiss drugmaker decided to voluntarily recall some products in the United States and move to improve quality standards at manufacturing sites.
Recent Posts
Categories